Roche unveils plans for its DNA sequencer that's been 18 years in the making
Has drug giant Roche finally cracked DNA sequencing? The company has recently claimed it can quickly and accurately decode the genome, in a way that's a major step forward for an industry that’s vital...
View ArticleDrugmakers tell court to keep hospitals out of their 340B rebate suits
Eli Lilly, Bristol Myers Squibb, Sanofi and Novartis are seeking to block a major hospital trade group from intervening in court cases over their proposed 340B drug rebate models. 340B Health and two...
View ArticleTrump’s HHS defends drug price negotiations in Novartis suit
Lawyers for the government gave the first substantive signal that the Trump administration will continue to defend Medicare drug price negotiations in court. In a Wednesday court brief, attorneys for...
View ArticleKevin Tang's Concentra tries to disrupt proposed Acelyrin-Alumis merger
Concentra Biosciences, the shell company from Tang Capital that tries to buy out struggling biotechs, has found another target, this time trying to throw a wrench in Acelyrin's merger plans with...
View ArticleMerck KGaA tees up changes to leadership team; Ex-CVS Health CEO joins Thermo...
→ Peter Guenter will retire as CEO of Merck KGaA’s healthcare business on June 1, one of several personnel moves that the German pharma announced earlier this week. Global R&D chief ...
View ArticlePfizer ends rollout of Beqvez, putting another dent in hemophilia gene...
Pfizer is ending the development and commercialization of its hemophilia B gene therapy Beqvez, the company confirmed in an emailed statement to Endpoints News. The company cited “limited interest...
View ArticleAchira raises $33M Nvidia-backed seed round, blending AI and physics in biotech
As he was testing new antivirals to halt a future pandemic, John Chodera encountered an unlikely set of new problems that ultimately helped lead to his new job. The computational chemist won
View ArticleFDA says Ozempic, Wegovy shortage is over
The FDA said Friday that the shortage of semaglutide, the main ingredient in Novo Nordisk’s GLP-1 drugs Ozempic and Wegovy, has been resolved after more than two years. The move could ...
View ArticleEli Lilly stockpiles $548M of oral weight loss drug ahead of launch
Eli Lilly has amassed a stockpile of soon-to-be-launched drugs and related materials, primarily its oral GLP-1 candidate orforglipron, worth more than half a billion dollars. Orforglipron will be ready...
View ArticleMore biotechs announce share buybacks; Cosette to buy Mayne Pharma
Plus, news about MeiraGTx, Hookipa and Poolbeg Pharma: A pair of $500M share buybacks: Exelixis and Neurocrine Biosciences each laid out plans to buy back half a ...
View ArticleBluebird bio to sell to investment funds after struggling to make money from...
A pair of investors will acquire bluebird bio in a deal worth only $29 million upfront after the gene therapy maker ran out of time and options. The company has struggled financially even as it ...
View ArticleTeva launches Stelara biosimilar at 85% discount as wider field emerges
Teva and its partner Alvotech on Friday followed Amgen in launching a biosimilar to Johnson & Johnson's blockbuster immunosuppressive biologic Stelara, offering a steep discount. The Stelara...
View ArticleCBER's deputy director departs as staff shakeup continues
Celia Witten, deputy director of the FDA's Center for Biologics Evaluation and Research, has left the FDA, adding to a wave of departures at the agency and across the federal health infrastructure as...
View ArticleFDA approves first drug to treat ultra-rare lipid storage disease
The FDA on Friday approved Mirum Pharmaceuticals' Ctexli to treat adults with cerebrotendinous xanthomatosis (CTX), a rare, progressive and genetic disease. The approval is based on the...
View ArticleBourla praises Trump as RFK Jr. preps vaccine review; Will CRISPR matter?;...
Good morning, and welcome back to Endpoints Weekly. Some of our biggest news this week came out of DC, where Pfizer CEO and incoming PhRMA chair Albert Bourla spoke in support of the Trump...
View ArticlePost-Hoc: Pharma CEOs' alternative reality with Trump
Tiki Barber gave me a brief glimmer of hope this week. “There’s an elephant in the room,” the former New York Giants football star said, perched in a leather chair, talking with GSK CEO Emma ...
View ArticleSanofi, Teva bolster case for IBD drug with Phase 2 data, despite potential...
Sanofi and Teva’s inflammatory bowel disease candidate could make €1 billion ($1.05 billion) a year by 2032, Leerink analysts said on Sunday. The blockbuster projection comes after the partners shared...
View ArticleAmgen plans further $200M investment in new tech facility in India
Amgen said it will spend an additional $200 million on its new technology center in Hyderabad, India, throughout 2025, with other investments to come over the next few years. “Hyderabad is rapidly...
View ArticlePfizer hires former top FDA deputy Patrizia Cavazzoni as CMO
Patrizia Cavazzoni, the FDA’s former head of drug regulation, will become Pfizer’s new chief medical officer, Endpoints News has learned. Cavazzoni led the FDA’s Center for Drug Evaluation and Research...
View Article